Tim Smith

In a study evaluating bulevirtide as monotherapy, investigators found the antiviral to be safe and tolerable following nearly a year of treatment.

Investigators highlighted the long-term cost-effectiveness of routine HCV screening as well as linkage-to-care for high-risk patients in emergency departments.

The data from these meta-analyses highlight the value of developing systems to promote daily toothbrushing among those who have been hospitalized and, particularly, those on mechanical ventilation.

The federal agency gave the nod to Verrica Pharmaceuticals for its therapy, VP-102 (Ycanthe), for molluscum contagiosum (molluscum), making it the first treatment indicated for the viral-borne skin disease.